RT Journal Article
SR Electronic
T1 Tocilizumab and steroid treatment in patients with COVID-19 pneumonia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.22.20133413
DO 10.1101/2020.06.22.20133413
A1 Mikulska, Malgorzata
A1 Nicolini, Laura Ambra
A1 Signori, Alessio
A1 Di Biagio, Antonio
A1 Sepulcri, Chiara
A1 Russo, Chiara
A1 Dettori, Silvia
A1 Berruti, arco
A1 Sormani, Maria Pia
A1 Giacobbe, Daniele Roberto
A1 Vena, Antonio
A1 De Maria, Andrea
A1 Dentone, Chiara
A1 Taramasso, Lucia
A1 Mirabella, Michele
A1 Magnasco, Laura
A1 Mora, Sara
A1 Delfino, Emanuele
A1 Toscanini, Federica
A1 Balletto, Elisa
A1 Alessandrini, Anna Ida
A1 Baldi, Federico
A1 Briano, Federica
A1 Camera, Marco
A1 Dodi, Ferdinando
A1 Ferrazin, Antonio
A1 Labate, Laura
A1 Mazzarello, Giovanni
A1 Pincino, Rachele
A1 Portunato, Federica
A1 Tutino, Stefania
A1 Barisione, Emanuela
A1 Bruzzone, Bianca
A1 Orsi, Andrea
A1 Schenone, Eva
A1 Rosseti, Nirmala
A1 Sasso, Elisabetta
A1 Rin, Giorgio Da
A1 Pelosi, Paolo
A1 Beltramini, Sabrina
A1 Giacomini, Mauro
A1 Icardi, Giancarlo
A1 Gratarola, Angelo
A1 Bassetti, Matteo
YR 2020
UL http://medrxiv.org/content/early/2020/06/26/2020.06.22.20133413.abstract
AB Introduction Coronavirus disease 2019 (COVID-19) can lead to respiratory failure due to severe immune response. Treatment targeting this immune response might be beneficial but there is limited evidence on its efficacy.The aim of this study was to determine if early treatment of patients with COVID-19 pneumonia with tocilizumab and/or steroids was associated with better outcome.Methods This observational single-center study included patients with COVID-19 pneumonia who were not intubated and received either standard of care (SOC, controls) or SOC plus early (within 3 days from hospital admission) anti-inflammatory treatment. SOC consisted of hydroxychloroquine 400mg bid plus, in those admitted before March 24th, also darunavir/ritonavir. Anti-inflammatory treatment consisted of either tocilizumab (8mg/kg intravenously or 162mg subcutaneously) or methylprednisolone 1 mg/kg for 5 days or both. Failure was defined as intubation or death, and the endpoints were failure-free survival (primary endpoint) and overall survival (secondary) at day 30. Difference between the groups was estimated as Hazard Ratio by a propensity score weighted Cox regression analysis (HROW).Results Overall, 196 adults were included in the analyses. They were mainly male (67.4%), with comorbidities (78.1%) and severe COVID-19 pneumonia (83.7%). Median age was 67.9 years (range, 30-100) and median PaO2/FiO2 200 mmHg (IQR 133-289). Among them, 130 received early anti-inflammatory treatment with: tocilizumab (n=29, 22.3%), methylprednisolone (n=45, 34.6%), or both (n=56, 43.1%). The adjusted failure-free survival among tocilizumab/methylprednisolone/SOC treated patients vs. SOC was 80.8% (95%CI, 72.8-86.7) vs. 64.1% (95%CI, 51.3-74.0), HROW 0.48, 95%CI, 0.23-0.99; p=0.049. The overall survival among tocilizumab/methylprednisolone/SOC patients vs. SOC was 85.9% (95%CI, 80.7-92.6) vs. 71.9% (95%CI, 46-73), HROW 0.41, 95%CI: 0.19-0.89, p=0.025.Conclusion Early adjunctive treatment with tocilizumab, methylprednisolone or both may improve outcomes in non-intubated patients with COVID-19 pneumonia.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot registeredFunding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patients provided an informed consent for treatment with off label agents according to the local protocol approved by Hospital Authorities, for data collection and for participation in the study. The study was carried out in accordance with the principles of the Declaration of Helsinki and approved by the Regional Ethic Committee (N. CER Liguria 114/2020-ID 10420).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.